Neurotrophic KeratitisSymptoms, Doctors, Treatments, Advances & More
Learn About Neurotrophic Keratitis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Eye Consultants Of Pennsylvania PC
Kevin Shah is an Ophthalmologist practicing medicine in Lebanon, Pennsylvania. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Neurotrophic Keratitis. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Neurotrophic Keratitis, Cataract, Pterygium, and Interstitial Keratitis. Dr. Shah is board certified in American Board Of Ophthalmology.
Guillermo Amescua is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Amescua is rated as a Distinguished provider by MediFind in the treatment of Neurotrophic Keratitis. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Interstitial Keratitis, Amebiasis, Scleritis, Corneal Transplant, and Vitrectomy. Dr. Amescua is currently accepting new patients.
Anat Galor is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Galor is rated as a Distinguished provider by MediFind in the treatment of Neurotrophic Keratitis. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Dry Eye Syndrome, Pterygium, Pinguecula, Cataract Removal, and Corneal Transplant. Dr. Galor is currently accepting new patients.
Summary: The Investigators hypothesize that the recalcitrant nature of ocular GVHD may be related to corneal nerve damage and corneal hypoesthesia. The investigators aim to study the prevalence of corneal hypoesthesia in GVHD patients and its correlation with ocular surface changes.
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.